October 01, 2025 a 08:39 am
EW: Analysts Ratings - Edwards Lifesciences Corporation
Edwards Lifesciences Corporation is experiencing a stable trend with a significant amount of "Hold" ratings persisting over time. While "Strong Buy" and "Buy" ratings remain notable, and there is a minimal presence of "Sell" recommendations, indicating general confidence in the company's operations, especially in the structural heart disease and critical care market sectors.
Historical Stock Grades
| Recommendation | Count | Score |
|---|---|---|
| Strong Buy | 4 | |
| Buy | 13 | |
| Hold | 15 | |
| Sell | 1 | |
| Strong Sell | 0 |
Sentiment Development
The sentiment for Edwards Lifesciences shows a consistent number of ratings, with notable stability in the "Hold" and "Buy" categories. Recent months display a slight decrease in "Strong Buy" recommendations while "Hold" ratings experienced a subtle increase. This suggests analysts are becoming more cautious, balancing their optimism with conservative outlooks as market contexts fluctuate.
- The overall number of ratings has remained stable over the months.
- There is a noticeable downward trend in "Strong Buy" ratings from 7 in Fall 2024 to 4 by October 2025.
- "Hold" recommendations have been gaining momentum, peaking at 19 then reducing to 15.
Percentage Trends
Over the last year, there has been a noticeable shift from more aggressive "Strong Buy" stances to more moderate positions such as "Buy" and "Hold." This shift suggests a cautious approach among analysts as they assess market conditions and the company's performance.
- There has been a reduction in "Strong Buy" ratings from 23% to approximately 13% over the past 12 months.
- "Hold" ratings have increased from approximately 10% to 31% in the same period, indicating increased caution.
- This shift illustrates an increasing consensus around a more cautious stance towards the company's financial outlook.
Latest Analyst Recommendations
Recent recommendations from analysts reveal stability, with most maintaining their ratings. This consistent trend indicates continued confidence in the stock’s long-term viability, with no immediate signs of volatility or drastic changes.
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2025-09-22 | Buy | Buy | Stifel |
| 2025-08-07 | Overweight | Overweight | Wells Fargo |
| 2025-07-25 | Neutral | Neutral | Baird |
| 2025-07-25 | Buy | Buy | Deutsche Bank |
| 2025-07-25 | Outperform | Outperform | RBC Capital |
Analyst Recommendations with Change of Opinion
In cases where analyst opinions have shifted, there are instances of both upgrades and downgrades. This mixed movement suggests that some analysts see potential upside to the stock, while others might be responding to perceived risks or market pressures.
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2025-04-24 | Overweight | Neutral | Piper Sandler |
| 2025-01-30 | Buy | Hold | Stifel |
| 2025-01-16 | Underperform | Peer Perform | Wolfe Research |
| 2024-12-16 | Buy | Neutral | B of A Securities |
| 2024-09-18 | Hold | Buy | Jefferies |
Interpretation
Overall, the analyst sentiment for Edwards Lifesciences reflects a degree of stability with a prudent, cautious tone. The persistence of "Hold" and "Buy" ratings suggests steady confidence but also a level of restraint, as evidenced by fewer "Strong Buy" signals. While opinion changes have occurred, the stock appears not to elicit extreme bullish or bearish shifts, indicating a stable outlook.
Conclusion
Edwards Lifesciences Corporation appears to be a stable investment choice within its market sector, backed by consistently moderate analyst sentiment. While the decrease in "Strong Buy" ratings may signal some caution, the increase in "Hold" ratings suggests analysts are taking a more balanced approach. The commitment to technologies in heart disease and critical care continues to solidify the company’s market position, offering resilience in varying economic climates. The blend of stable yet cautious sentiments suggests a poised company maintaining its prominence in a dynamic market.